Quick Answer
Rapport Therapeutics, Inc. reported Cash And Cash Equivalents At Carrying Value of $52.65 million for the year ending 2025.
- Rapport Therapeutics, Inc. showed a decrease of -7.3% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
- This data is from Rapport Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 10, 2026.
- XBRL data for this metric is available from 2023 to 2025 (3 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2023: $79.53 million | Q3 2023: $159.41 million | Q1 2024: $74.27 million | Q2 2024: $110.16 million | Q3 2024: $39.31 million | Q1 2025: $57.60 million | Q2 2025: $55.07 million | Q3 2025: $251.36 million.
- Over the full 3 years of available data (2023 to 2025), Rapport Therapeutics, Inc.'s Cash And Cash Equivalents At Carrying Value has declined by 25.0%.
- Historical annual values: Fiscal year 2025: $52.65 million | Fiscal year 2024: $56.81 million | Fiscal year 2023: $70.17 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: